Yervoy (ipilimumab) is a drug used in the treatment of metastatic melanoma. According to the clinical trials, Yervoy has shown to be effective in improving the overall survival rate of patients with metastatic melanoma. In a study conducted by the National Cancer Institute, patients who received Yervoy had a median survival rate of 10 months, compared to 6.4 months for those who received a placebo [2].

However, Yervoy is not a standalone treatment option for metastatic melanoma. Combination therapy with other drugs, such as Opdivo (nivolumab), has shown to be more effective in treating advanced melanoma. In a clinical trial, patients who received a combination of Yervoy and Opdivo had a higher response rate (58%) compared to those who received Yervoy alone (19%) [2]. Additionally, the combination therapy has shown to improve progression-free survival and overall survival rates [2].

Despite the promising results, Yervoy and combination therapy may cause severe side effects. According to the Melanoma Research Alliance, the side effects of Yervoy and combination therapy include diarrhea, colitis, hepatitis, endocrinopathies, and neuropathies [3]. Therefore, it is essential to discuss the potential risks and benefits of the treatment options with a healthcare provider.

In conclusion, Yervoy has shown to be effective in improving the overall survival rate of patients with metastatic melanoma. However, combination therapy with other drugs, such as Opdivo, has shown to be more effective in treating advanced melanoma. It is important to discuss the potential risks and benefits of the treatment options with a healthcare provider.

Sources:
[2] https://www.opdivo.com/metastatic-melanoma/about-opdivo/clinical-trial-results/combination-therapy
[3] https://www.curemelanoma.org/blog/article/full-sails-ahead-immunotherapy-shows-continued-survival-benefit-for-patients-facing-advanced-melanoma
[4] https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY